Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 5/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CYBB | P04839 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16747749 | 1.00 | OPRK1 (0.53) | OPRK1OPRM1OPRD1CYP2D6CHRNA7 | |
| SCHEMBL14996104 | 1.00 | OPRK1 (0.53) | OPRK1OPRM1OPRD1CYP2D6CHRNA7 | |
| SCHEMBL21443742 | 0.91 | OPRK1 (0.55) | OPRK1OPRM1OPRD1CYP2D6CHRNA7 | |
| SCHEMBL13013393 | 0.89 | OPRM1 (0.53) | OPRK1OPRM1OPRD1CYP2D6CHRNA7 | |
| SCHEMBL18874426 | 0.89 | OPRK1 (0.51) | OPRK1OPRM1OPRD1CYP2D6CHRNA7 | |
| SCHEMBL16711062 | 0.88 | OPRK1 (0.50) | OPRK1OPRM1OPRD1CYP2D6CHRNA7 | |
| SCHEMBL16743664 | 0.87 | OPRM1 (0.56) | OPRK1OPRM1OPRD1CYP2D6LMNA | |
| SCHEMBL15732206 | 0.87 | OPRM1 (0.56) | OPRK1OPRM1OPRD1CYP2D6LMNA | |
| SCHEMBL16015653 | 0.87 | OPRM1 (0.51) | OPRK1OPRM1OPRD1CYP2D6CHRNA7 | |
| SCHEMBL15732207 | 0.86 | OPRK1 (0.39) | OPRK1OPRM1OPRD1CYP2D6CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150164886-A9 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | MALLINCKRODT INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-9040726-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140323426-A1 | USE OF OPIOID ANTAGONISTS TO ATTENUATE ENDOTHELIAL CELL PROLIFERATION AND MIGRATION | THE UNIVERSITY OF CHICAGO | 2014-10-30 | — | — | US | disclosed |
| US-8524731-B2 | Angiogenesis inhibitors; anti-VEGF monoclonal antibody | THE UNIVERSITY OF CHICAGO (US) | 2013-09-03 | — | — | US | disclosed |
| US-8518962-B2 | Use of opioid antagonists | THE UNIVERSITY OF CHICAGO (US) | 2013-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323426-A1 | USE OF OPIOID ANTAGONISTS TO ATTENUATE ENDOTHELIAL CELL PROLIFERATION AND MIGRATION | OGFR, OPRK1, OPRL1 | OPRK1 2/4885OPRM1 4/4885OPRD1 5/4885 |
| US-20150164886-A9 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | RAN, RANBP1, NCLN | OPRK1 527/4885OPRM1 60/4885OPRD1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.